Latest California Healthline Stories
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
Among hurdles: Older adults may have multiple illnesses that could complicate research or they might be unable to manage the commute.